Curriculum Vitae ARUN K. KALRA, MD

Similar documents
An D. Nguyen, MD Curriculum Vitae

CURRICULUM VITAE. San Diego Cancer Center/ Medical Group of North County, Inc. Encinitas, CA (760) (760) (760) fax

Velcade (bortezomib)

Velcade (bortezomib)

EMERGING THERAPIES FOR BLOOD CANCERS:

Bortezomib (Velcade)

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT

National Horizon Scanning Centre. Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer. December 2007

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT

2008 Oncology Pharmacy Preparatory Review Course Learning Objectives

CURRICULUM VITAE. Wendy Miller Rashidi, M.D., FAAFP, ABHIM-C, IFM-C

Summary of Research and Writing Activities in Oncology

2010 Oncology Pharmacy Preparatory Review Course for Home Study Learning Objectives

CENTER FOR CLINICAL TRIALS St. Luke s Medical Center. Ongoing Clinical Trials CANCER INSTITUTE (36)

UNIVERSITY HOSPITAL OF HERAKLION DEPARTMENT OF HAEMATOLOGY

Curriculum Vitae, Nirav S. Patel, M.D. Nirav S. Patel, M.D. Collaborative Neuroscience Network, LLC.

Gerald E. Turlo, M.D.

Curriculum Vitae Hui Yuan, MD

MIKE Y. JEONG, DO, MPH, CMD

IRB INDICATION Number ENROLLED

SHORT C. V. Meletios A. Dimopoulos, MD

BLOOD AND LYMPH CANCERS

Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD

Curriculum Vitae, Lara Goenjian Shirikjian, D.O. Lara Goenjian Shirikjian, D.O. Collaborative Neuroscience Network, LLC

Curriculum Vitae for: GIL LICHTSHEIN, M.D. Gil Lichtshein, M.D., P.A West Camino Real, Suite 220 Boca Raton, FL 33433

Jason Luke, MD, FACP Assistant Professor of Medicine University of Chicago, USA BRIEF INTRODUCTION

In this program you will learn

which to base economic assessment of the products available to treat this hematologic

CLINICAL TRIALS ACC. Jul 2016

Jefferson Kimmel Cancer Center Network Presents: The Clinical Research E-News. January 14, 2009

We re Reaching Ludicrous Speed: New Immunotherapy Oncology Medications

Child and Family Psychiatry

CME Information LEARNING OBJECTIVES

PRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019

ANIL K. CHAGARLAMUDI, M.D. CURRICULUM VITAE

Kalyan Nadiminti, MBBS 4/13/18

Overview PAUL J. PETRUSKA, M.D.

Our Clinical Trials. Oncology

SUBURBAN LUNG ASSOCIATES, S.C. Eberle Medical Building, 800 Biesterfield road, Suite 510 Elk Grove Village, IL Sleep Group

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December

Clinical Research Institute HUCH Sponsored, fully signed Clinical Trial Agreements (except grants)

H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS

CURRICULUM VITAE. Associate Clinical Professor of Medicine, UCSF Medical Director, Acute Care for Elders Unit, San Francisco General Hospital

Mark Steven Schnitzer, M.D., F.A.C.S.

Background Information

: Ajou University College of Medicine, Suwon, Korea; Ajou University College of Medicine, Graduate

New Biological and Immunological Therapies for Cancer

George Shannon, MSG, PhD

Education and Training

National Cancer Drugs Fund List - Approved

DIVISION OF HEMATOLOGY AND ONCOLOGY

CURRICULUM VITAE. Catherine J. Lesnick

National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:

GAURAV DHAR, M.D. Curriculum Vitae

STUDY DESIGN. VMP 6-week cycles, total of 9 cycles. Figure 2. Alcyone study design. Countries housing study sites are shaded in gold.

Key ASCO Presentations Issue 4, Effects of Zoledronic Acid on Overall Survival in Newly Diagnosed Multiple Myeloma (MM)

MARY BETH VALIULIS, M.D. CURRICULUM VITAE 2016

DIANA ECHEVERRY-FRANCK CURRICULUM VITAE

Rituximab, and autologous stem cell collection rate after induction therapy with Bortezomib-Rituximab. 4 Not yet recruiting

University of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan

To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors

The Clinical Research E-News

UNIVERSITY OF MIAMI Curriculum Vitae Standard Format. 2. Name: Jesus Alberto Gomez-(Perez)

Curriculum Vitae, Nirav S. Patel, M.D. Nirav S. Patel, M.D. Collaborative Neuroscience Network, LLC Redondo Avenue, Suites 415 & 500

Denosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma

2018 UPDATE IN HEMATOLOGIC MALIGNANCIES with Proceedings from International Medical Meetings

West Virginia University School of Medicine, Morgantown, West Virginia

Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona

Target date to recruit patients agreed? Target range minimum. Target range maximum. Agreed 1 1 Agreed 01/01/ /01/2016 Recruitment Finished

MEDICAL PRIOR AUTHORIZATION

Implementation of Hematology- Oncology Education Program. Amir Steinberg, MD Samuel Oschin Comprehensive Cancer Center Cedars-Sinai Medical Center

CURRICULUM VITAE PERSONAL DETAILS: RAHAL, MOHAMED

Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center

Grand Valley State University, Allendale, Michigan B.S. Biomedical Sciences Dean s List

Curriculum Vitae, Edward H. Ortiz, M.D.

Open clinical uro-oncology trials in Canada

GLENNA TOLBERT, M.D. DIPLOMATE, ABPMR: SPINAL CORD MEDICINE QUALIFIED MEDICAL EXAMINER

Open Trials as of end of March 2016

Experience with bortezomib (Velcade) in multiple myeloma. Peter Černelč Clinical center Ljubljana Department of Haematology

Medical Industrial Evaluators Wilshire Boulevard, Suite 830 Los Angeles, California (310) Fax: (310)

Famini, Pouyan, M.D. Medicine/Endocrinology Curriculum Vitae

Peking University People's Hospital, Peking University Institute of Hematology

University of California, San Francisco CURRICULUM VITAE. Nancy Dudley, RN, PhD

Prior Authorization Required: Yes as shown below

CURRICULUM VITAE JASMEET K. GILL

Revlimid. Revlimid (lenalidomide) Description. Section: Prescription Drugs Effective Date: July 1, 2015

Dennis J Slamon, MD, PhD

Pharmacy Medical Necessity Guidelines: Afinitor (everolimus) & Afinitor Disperz (everolimus tablets for oral suspension)

BreastCancerAdvisor by DR. SILVANA MARTINO January 2014

07/ /2013 Internal Medicine Residency at John H. Stroger Jr. Hospital of Cook County, Chicago IL

The Development of Pediatric Oncology in Turkey:

Highlights from the 2017 Annual Meeting of the American Society of Hematology

Executive Coaching W. Executive Coaching / Anger Management for Disruptive Physicians. Fairbanks, Alaska Palm Desert, Calif.

My name is Dr. David Ilson, Professor of Medicine at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center in New York, New York.

DIAGNOSIS AND TREATMENT OF WALDENSTRÖM S MACROGLOBULINAEMIA IN THE NETHERLANDS. Monique Minnema UMC Utrecht

CREDIT DESIGNATION STATEMENT

Open clinical uro-oncology trials in Canada

7 Recruiting Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia Condition: Waldenstrom's Macroglobulinemia

TRANSPARENCY COMMITTEE OPINION. 27 January 2010

Sarah A. Vlach, M.D. Curriculum Vitae Page 1

Transcription:

Curriculum Vitae ARUN K. KALRA, MD Office: CCARE California Cancer Associates in Research and Excellence 39755 Date St. Suite 103 Murrieta, California 92563 01/2017 to current. Arun Kalra MD Inc. 09/2016 to 02/01/2017 Oncology Hematology 39755 Date St. Suite 103 Murrieta, California 92563 Affiliating Medical Centers: Loma Linda University Med CTR., 28062 Baxter RD Murrieta CA 92563 Inland Valley Hospital 36485 Inland Valley Dr. Wildomar CA 92595 Rancho Springs Medical Center 25500 Medical Center Dr. Murrieta CA 92562 Temecula Valley Hospital 31700 Temecula Parkway Temecula Ca 92592 Hemet Valley Medical Center 1117 E. Devonshire Avenue Hemet, California 92543 08/2016 to present 03/01/2017 to present 03/01/2017 to present 02/2016 to present 10/2013 to Present Eisenhower Medical Center 07/2008 to 07/2015 39000 Bob Hope Drive Rancho Mirage, California 92270 Desert Regional Medical Center 07/2008 to 03/01/2017 1150 North Indian Canyon Drive Palm Springs, California 92262 1 P age

Education: PhD Candidacy in Cancer Pharmacology 03/1982 to 03/1984 State University of New York State University of New York 06/1982 to 06/1983 Master s Degree, Natural Sciences All India Institute of Medical Sciences 08/1971 to 12/1976 New Delhi, India MB,B.S. (M.D.) Undergraduate, Pre-Medical Degree 07/1970 to 06/1971 DAV College Jullundur City, Punjab, India Residency: Fellowships: Categorical Internal Medicine Residency 05/1977 to 06/1980 Wayne State University Medical Center Detroit, Michigan Medical Oncology Fellowship 07/1980 to 06/1982 Roswell Park Memorial Institute Senior Research Fellowship 07/1982 to 03/1984 Roswell Park Memorial Institute Board Certification: Diplomate- Internal Medicine- ABIM 09/1980 Diplomate- Medical Oncology- ABIM 09/1985 Interests All aspects of Medical Oncology, clinical and research, with special interest in: Personalized care of cancer patients-based on genetic analysis. Geriatric Oncology Value based care Human side of cancer Positions and Appointments: Hematology Oncology Specialists 02/2016 to 11/2016 Hemet Ca 93544 Apex Hematology/Oncology Medical Group 10/2013 to 02/2016 Hemet, California Desert Cancer Care, Inc. 07/2009 to 10/2013 Rancho Mirage, California 2 P age

Comprehensive Cancer Center 07/2008 to 06/2009 Palm Springs, California UCLA Westwood Hospital 01/2007 to 06/2008 Westwood, California Century City Doctor s Hospital 02/2006 to 06/2008 Century City, California Brotman Hospital 02/2006 to 07/2008 Culver City, California St. John s Hospital 02/2005 to 06/2008 Santa Monica, California UCLA Santa Monica Hospital 02/2006 to 06/2008 Santa Monica, California Sarcoma Oncology Center 09/2005 to 07/2008 Sant P. Chawla, MD Santa Monica, California 90403 Kaiser Permanente/CompHealth 06/2005 to 09/2005 West Los Angeles, California 90234. Sterling Rock Falls Clinic 05/1990-05/2005 Sterling, Illinois 61081 Guthrie Medical Group 06/1986-05/1990 Corning, New York 14830 VA Medical Center 01/1986 to 05/1990 Bath, New York Corning Medical and Surgical Associates 05/1984 to 06/1986 Corning, New York (later purchased by Guthrie Medical Group) Teaching Appointments Clinical Faculty Assistant Professor Internal Medicine Western University of Health Sciences/College of Osteopathic Medicine of the Pacific, California 08/2014 to present Voluntary Faculty 2006 to 2008 Department of Oncology University of Southern California Los Angeles, California Clinical Instructor 1984 to 1990 University of Rochester Medical School Rochester, New York 3 P age

Clinical Instructor 1980 to 1984 State University of New York Medical School Honors and Awards: Hospital Recognition 1984 to 1990 Bridge Builder Physician Recognition (three awards) Corning Hospital, Corning, New York Research Awards 1983 Gold Medal, Best Research Report Roswell Park Cancer Institute Medical School Standing 1971 to 1975 Rated among top 25% of students in the class Other Awards University Dean s Merit List Scholar, Punjab University 1971 National Science Talent Search Scholar, India. 1970 National High School Boards Salutatorian, India 1969 Licenses: California Active Publications: 1. Taxane, Doxorubicin and Dexrazoxone in adjuvant chemotherapy of high-risk breast carcinoma. Programs and Proceedings, American Society of Clinical Oncologists Annual Meeting 2001, Abstract #1801. 2. Prolymphocytic Lymphoma in a patient with colon carcinoma. Program and proceedings American Society of Clinical Oncologists Annual Meeting 1993, Abstract #1300. 3. Familial Occurrence of Hairy Cell Leukemia in Two Brothers- A Case Report. Programs and proceedings American Society of Clinical Oncologists Annual Meeting 1992. Abstract #896 Research Experience: 2009 Sub-investigator- Novartis Pharmaceutical Corp: A Prospective, Randomized, Multi-Center, Three-arm Trial of the Continued Efficacy and Safety of Zometa in Patients with Documented Bone Metastases from Breast Cancer. Protocol # CZOL446E2352. 2009 Sub-investigator- Gloucester Pharmaceuticals: A Phase II Trial of Romidepsin and Bortezomib for Patients with Multiple Myeloma Relapsed or Refractory Disease. Protocol # GPI-08-0006 4 P age

2009 Sub-investigator- Millennium Pharma: Phase IIIB, Randomized Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma who are not considered candidates with High Dose Chemotherapy and Autologous Stem Cell Transplantation. Velcade, Thalidomide and Dexamethasone (VTD) vs Velcade and Dexamethasone (VD) vs Velcade, Melphalan and Prednisone (VMP). Protocol # C05009 2009 Sub-investigator- Oncotherapeutics: A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for Patients with Newly Diagnosed Multiple Myeloma. Protocol # X05272/DOIXILMMY2010 2009 Principle Investigator- Sanofi Aventis US, Inc: A Multinational, Randomized, Double-Blind Study Comparing the Efficacy of Aflibercept once every two (2) weeks versus Placebo in Patients Treated with Gemcitabine for Metastatic Pancreatic Cancer. Protocol #EFC10547 (Vanilla) 2008/09 Sub-investigator- Amgen, Inc.: An Open-Label, Multi-Center, Phase 2 Safety and Efficacy Study of Denosumab (AMG 162) in Subjects with Recurrent or Unresectable Giant Cell Tumor (GCT) of Bone. Protocol #20040215 2008/09 Sub-investigator- AOI Pharmacy, Inc: Sarcoma Alliance for Research Through Collaboration (SARC) Multicenter Trial: A Phase II Trial of Perifosine in Patients with Chemo-insensitive Sarcoma. Protocol #Perfosine#214 2008/09 Sub-investigator- SARC: A Multicenter, Open Label Single Arm Study of YONDELIS (trabectidin) for Subjects with Locally Advanced or Metastatic Soft Tissue Sarcoma who have relapsed or are refractory to standard of care treatment. Protocol #JOHNS006/05-045 2008/09 Sub-investigator- Amgen, Inc: A Phase 1b/2 Study to Evaluate the Safety and Efficacy of AmG655 or AMG 479 in Combination with Gemcitabine and First-Line Therapy for Metastatic Pancreatic Cancer. Protocol #20060323 5 P age